Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
14,731
archived clinical trials in
Psychiatric

Long-Term Safety Extension Trial of Asenapine in Bipolar 1 Disorder Participants Who Completed Protocol P05691 (P05692)
A Multicenter, Double-Blind, Fixed-Dose, Long-Term Extension Trial of the Safety of Asenapine in Subjects Diagnosed With Bipolar 1 Disorder Who Completed Protocol P05691 (Formerly 041044) (Phase3B, Protocol P05692 [Formerly 041045])
Status: Enrolling
Updated:  4/22/2014
Clinical Research Facility
mi
from
Fort Lauderdale, FL
Long-Term Safety Extension Trial of Asenapine in Bipolar 1 Disorder Participants Who Completed Protocol P05691 (P05692)
A Multicenter, Double-Blind, Fixed-Dose, Long-Term Extension Trial of the Safety of Asenapine in Subjects Diagnosed With Bipolar 1 Disorder Who Completed Protocol P05691 (Formerly 041044) (Phase3B, Protocol P05692 [Formerly 041045])
Status: Enrolling
Updated: 4/22/2014
Clinical Research Facility
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
Long-Term Safety Extension Trial of Asenapine in Bipolar 1 Disorder Participants Who Completed Protocol P05691 (P05692)
A Multicenter, Double-Blind, Fixed-Dose, Long-Term Extension Trial of the Safety of Asenapine in Subjects Diagnosed With Bipolar 1 Disorder Who Completed Protocol P05691 (Formerly 041044) (Phase3B, Protocol P05692 [Formerly 041045])
Status: Enrolling
Updated:  4/22/2014
Clinical Research Facility
mi
from
Ft. Lauderdale, FL
Long-Term Safety Extension Trial of Asenapine in Bipolar 1 Disorder Participants Who Completed Protocol P05691 (P05692)
A Multicenter, Double-Blind, Fixed-Dose, Long-Term Extension Trial of the Safety of Asenapine in Subjects Diagnosed With Bipolar 1 Disorder Who Completed Protocol P05691 (Formerly 041044) (Phase3B, Protocol P05692 [Formerly 041045])
Status: Enrolling
Updated: 4/22/2014
Clinical Research Facility
mi
from
Ft. Lauderdale, FL
Click here to add this to my saved trials
Long-Term Safety Extension Trial of Asenapine in Bipolar 1 Disorder Participants Who Completed Protocol P05691 (P05692)
A Multicenter, Double-Blind, Fixed-Dose, Long-Term Extension Trial of the Safety of Asenapine in Subjects Diagnosed With Bipolar 1 Disorder Who Completed Protocol P05691 (Formerly 041044) (Phase3B, Protocol P05692 [Formerly 041045])
Status: Enrolling
Updated:  4/22/2014
Clinical Research Facility
mi
from
Maitland, FL
Long-Term Safety Extension Trial of Asenapine in Bipolar 1 Disorder Participants Who Completed Protocol P05691 (P05692)
A Multicenter, Double-Blind, Fixed-Dose, Long-Term Extension Trial of the Safety of Asenapine in Subjects Diagnosed With Bipolar 1 Disorder Who Completed Protocol P05691 (Formerly 041044) (Phase3B, Protocol P05692 [Formerly 041045])
Status: Enrolling
Updated: 4/22/2014
Clinical Research Facility
mi
from
Maitland, FL
Click here to add this to my saved trials
Long-Term Safety Extension Trial of Asenapine in Bipolar 1 Disorder Participants Who Completed Protocol P05691 (P05692)
A Multicenter, Double-Blind, Fixed-Dose, Long-Term Extension Trial of the Safety of Asenapine in Subjects Diagnosed With Bipolar 1 Disorder Who Completed Protocol P05691 (Formerly 041044) (Phase3B, Protocol P05692 [Formerly 041045])
Status: Enrolling
Updated:  4/22/2014
Clinical Research Facility
mi
from
Topeka, KA
Long-Term Safety Extension Trial of Asenapine in Bipolar 1 Disorder Participants Who Completed Protocol P05691 (P05692)
A Multicenter, Double-Blind, Fixed-Dose, Long-Term Extension Trial of the Safety of Asenapine in Subjects Diagnosed With Bipolar 1 Disorder Who Completed Protocol P05691 (Formerly 041044) (Phase3B, Protocol P05692 [Formerly 041045])
Status: Enrolling
Updated: 4/22/2014
Clinical Research Facility
mi
from
Topeka, KA
Click here to add this to my saved trials
Long-Term Safety Extension Trial of Asenapine in Bipolar 1 Disorder Participants Who Completed Protocol P05691 (P05692)
A Multicenter, Double-Blind, Fixed-Dose, Long-Term Extension Trial of the Safety of Asenapine in Subjects Diagnosed With Bipolar 1 Disorder Who Completed Protocol P05691 (Formerly 041044) (Phase3B, Protocol P05692 [Formerly 041045])
Status: Enrolling
Updated:  4/22/2014
Clinical Research Facility
mi
from
Lake Charles, LA
Long-Term Safety Extension Trial of Asenapine in Bipolar 1 Disorder Participants Who Completed Protocol P05691 (P05692)
A Multicenter, Double-Blind, Fixed-Dose, Long-Term Extension Trial of the Safety of Asenapine in Subjects Diagnosed With Bipolar 1 Disorder Who Completed Protocol P05691 (Formerly 041044) (Phase3B, Protocol P05692 [Formerly 041045])
Status: Enrolling
Updated: 4/22/2014
Clinical Research Facility
mi
from
Lake Charles, LA
Click here to add this to my saved trials
Long-Term Safety Extension Trial of Asenapine in Bipolar 1 Disorder Participants Who Completed Protocol P05691 (P05692)
A Multicenter, Double-Blind, Fixed-Dose, Long-Term Extension Trial of the Safety of Asenapine in Subjects Diagnosed With Bipolar 1 Disorder Who Completed Protocol P05691 (Formerly 041044) (Phase3B, Protocol P05692 [Formerly 041045])
Status: Enrolling
Updated:  4/22/2014
Clinical Research Facility
mi
from
Shreveport, LA
Long-Term Safety Extension Trial of Asenapine in Bipolar 1 Disorder Participants Who Completed Protocol P05691 (P05692)
A Multicenter, Double-Blind, Fixed-Dose, Long-Term Extension Trial of the Safety of Asenapine in Subjects Diagnosed With Bipolar 1 Disorder Who Completed Protocol P05691 (Formerly 041044) (Phase3B, Protocol P05692 [Formerly 041045])
Status: Enrolling
Updated: 4/22/2014
Clinical Research Facility
mi
from
Shreveport, LA
Click here to add this to my saved trials
Long-Term Safety Extension Trial of Asenapine in Bipolar 1 Disorder Participants Who Completed Protocol P05691 (P05692)
A Multicenter, Double-Blind, Fixed-Dose, Long-Term Extension Trial of the Safety of Asenapine in Subjects Diagnosed With Bipolar 1 Disorder Who Completed Protocol P05691 (Formerly 041044) (Phase3B, Protocol P05692 [Formerly 041045])
Status: Enrolling
Updated:  4/22/2014
Clinical Research Facility
mi
from
Flowood, MS
Long-Term Safety Extension Trial of Asenapine in Bipolar 1 Disorder Participants Who Completed Protocol P05691 (P05692)
A Multicenter, Double-Blind, Fixed-Dose, Long-Term Extension Trial of the Safety of Asenapine in Subjects Diagnosed With Bipolar 1 Disorder Who Completed Protocol P05691 (Formerly 041044) (Phase3B, Protocol P05692 [Formerly 041045])
Status: Enrolling
Updated: 4/22/2014
Clinical Research Facility
mi
from
Flowood, MS
Click here to add this to my saved trials
Long-Term Safety Extension Trial of Asenapine in Bipolar 1 Disorder Participants Who Completed Protocol P05691 (P05692)
A Multicenter, Double-Blind, Fixed-Dose, Long-Term Extension Trial of the Safety of Asenapine in Subjects Diagnosed With Bipolar 1 Disorder Who Completed Protocol P05691 (Formerly 041044) (Phase3B, Protocol P05692 [Formerly 041045])
Status: Enrolling
Updated:  4/22/2014
Clinical Research Facility
mi
from
St. Louis, MO
Long-Term Safety Extension Trial of Asenapine in Bipolar 1 Disorder Participants Who Completed Protocol P05691 (P05692)
A Multicenter, Double-Blind, Fixed-Dose, Long-Term Extension Trial of the Safety of Asenapine in Subjects Diagnosed With Bipolar 1 Disorder Who Completed Protocol P05691 (Formerly 041044) (Phase3B, Protocol P05692 [Formerly 041045])
Status: Enrolling
Updated: 4/22/2014
Clinical Research Facility
mi
from
St. Louis, MO
Click here to add this to my saved trials
Long-Term Safety Extension Trial of Asenapine in Bipolar 1 Disorder Participants Who Completed Protocol P05691 (P05692)
A Multicenter, Double-Blind, Fixed-Dose, Long-Term Extension Trial of the Safety of Asenapine in Subjects Diagnosed With Bipolar 1 Disorder Who Completed Protocol P05691 (Formerly 041044) (Phase3B, Protocol P05692 [Formerly 041045])
Status: Enrolling
Updated:  4/22/2014
Clinical Research Facility
mi
from
Willingboro, NJ
Long-Term Safety Extension Trial of Asenapine in Bipolar 1 Disorder Participants Who Completed Protocol P05691 (P05692)
A Multicenter, Double-Blind, Fixed-Dose, Long-Term Extension Trial of the Safety of Asenapine in Subjects Diagnosed With Bipolar 1 Disorder Who Completed Protocol P05691 (Formerly 041044) (Phase3B, Protocol P05692 [Formerly 041045])
Status: Enrolling
Updated: 4/22/2014
Clinical Research Facility
mi
from
Willingboro, NJ
Click here to add this to my saved trials
Long-Term Safety Extension Trial of Asenapine in Bipolar 1 Disorder Participants Who Completed Protocol P05691 (P05692)
A Multicenter, Double-Blind, Fixed-Dose, Long-Term Extension Trial of the Safety of Asenapine in Subjects Diagnosed With Bipolar 1 Disorder Who Completed Protocol P05691 (Formerly 041044) (Phase3B, Protocol P05692 [Formerly 041045])
Status: Enrolling
Updated:  4/22/2014
Clinical Research Facility
mi
from
Dayton, OH
Long-Term Safety Extension Trial of Asenapine in Bipolar 1 Disorder Participants Who Completed Protocol P05691 (P05692)
A Multicenter, Double-Blind, Fixed-Dose, Long-Term Extension Trial of the Safety of Asenapine in Subjects Diagnosed With Bipolar 1 Disorder Who Completed Protocol P05691 (Formerly 041044) (Phase3B, Protocol P05692 [Formerly 041045])
Status: Enrolling
Updated: 4/22/2014
Clinical Research Facility
mi
from
Dayton, OH
Click here to add this to my saved trials
Long-Term Safety Extension Trial of Asenapine in Bipolar 1 Disorder Participants Who Completed Protocol P05691 (P05692)
A Multicenter, Double-Blind, Fixed-Dose, Long-Term Extension Trial of the Safety of Asenapine in Subjects Diagnosed With Bipolar 1 Disorder Who Completed Protocol P05691 (Formerly 041044) (Phase3B, Protocol P05692 [Formerly 041045])
Status: Enrolling
Updated:  4/22/2014
Clinical Research Facility
mi
from
Philadelphia, PA
Long-Term Safety Extension Trial of Asenapine in Bipolar 1 Disorder Participants Who Completed Protocol P05691 (P05692)
A Multicenter, Double-Blind, Fixed-Dose, Long-Term Extension Trial of the Safety of Asenapine in Subjects Diagnosed With Bipolar 1 Disorder Who Completed Protocol P05691 (Formerly 041044) (Phase3B, Protocol P05692 [Formerly 041045])
Status: Enrolling
Updated: 4/22/2014
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Long-Term Safety Extension Trial of Asenapine in Bipolar 1 Disorder Participants Who Completed Protocol P05691 (P05692)
A Multicenter, Double-Blind, Fixed-Dose, Long-Term Extension Trial of the Safety of Asenapine in Subjects Diagnosed With Bipolar 1 Disorder Who Completed Protocol P05691 (Formerly 041044) (Phase3B, Protocol P05692 [Formerly 041045])
Status: Enrolling
Updated:  4/22/2014
Clinical Research Facility
mi
from
Charleston, SC
Long-Term Safety Extension Trial of Asenapine in Bipolar 1 Disorder Participants Who Completed Protocol P05691 (P05692)
A Multicenter, Double-Blind, Fixed-Dose, Long-Term Extension Trial of the Safety of Asenapine in Subjects Diagnosed With Bipolar 1 Disorder Who Completed Protocol P05691 (Formerly 041044) (Phase3B, Protocol P05692 [Formerly 041045])
Status: Enrolling
Updated: 4/22/2014
Clinical Research Facility
mi
from
Charleston, SC
Click here to add this to my saved trials
Long-Term Safety Extension Trial of Asenapine in Bipolar 1 Disorder Participants Who Completed Protocol P05691 (P05692)
A Multicenter, Double-Blind, Fixed-Dose, Long-Term Extension Trial of the Safety of Asenapine in Subjects Diagnosed With Bipolar 1 Disorder Who Completed Protocol P05691 (Formerly 041044) (Phase3B, Protocol P05692 [Formerly 041045])
Status: Enrolling
Updated:  4/22/2014
Clinical Research Facility
mi
from
Austin, TX
Long-Term Safety Extension Trial of Asenapine in Bipolar 1 Disorder Participants Who Completed Protocol P05691 (P05692)
A Multicenter, Double-Blind, Fixed-Dose, Long-Term Extension Trial of the Safety of Asenapine in Subjects Diagnosed With Bipolar 1 Disorder Who Completed Protocol P05691 (Formerly 041044) (Phase3B, Protocol P05692 [Formerly 041045])
Status: Enrolling
Updated: 4/22/2014
Clinical Research Facility
mi
from
Austin, TX
Click here to add this to my saved trials
Long-Term Safety Extension Trial of Asenapine in Bipolar 1 Disorder Participants Who Completed Protocol P05691 (P05692)
A Multicenter, Double-Blind, Fixed-Dose, Long-Term Extension Trial of the Safety of Asenapine in Subjects Diagnosed With Bipolar 1 Disorder Who Completed Protocol P05691 (Formerly 041044) (Phase3B, Protocol P05692 [Formerly 041045])
Status: Enrolling
Updated:  4/22/2014
Clinical Research Facility
mi
from
Austin, TX
Long-Term Safety Extension Trial of Asenapine in Bipolar 1 Disorder Participants Who Completed Protocol P05691 (P05692)
A Multicenter, Double-Blind, Fixed-Dose, Long-Term Extension Trial of the Safety of Asenapine in Subjects Diagnosed With Bipolar 1 Disorder Who Completed Protocol P05691 (Formerly 041044) (Phase3B, Protocol P05692 [Formerly 041045])
Status: Enrolling
Updated: 4/22/2014
Clinical Research Facility
mi
from
Austin, TX
Click here to add this to my saved trials
Long-Term Safety Extension Trial of Asenapine in Bipolar 1 Disorder Participants Who Completed Protocol P05691 (P05692)
A Multicenter, Double-Blind, Fixed-Dose, Long-Term Extension Trial of the Safety of Asenapine in Subjects Diagnosed With Bipolar 1 Disorder Who Completed Protocol P05691 (Formerly 041044) (Phase3B, Protocol P05692 [Formerly 041045])
Status: Enrolling
Updated:  4/22/2014
Clinical Research Facility
mi
from
Dallas, TX
Long-Term Safety Extension Trial of Asenapine in Bipolar 1 Disorder Participants Who Completed Protocol P05691 (P05692)
A Multicenter, Double-Blind, Fixed-Dose, Long-Term Extension Trial of the Safety of Asenapine in Subjects Diagnosed With Bipolar 1 Disorder Who Completed Protocol P05691 (Formerly 041044) (Phase3B, Protocol P05692 [Formerly 041045])
Status: Enrolling
Updated: 4/22/2014
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Long-Term Safety Extension Trial of Asenapine in Bipolar 1 Disorder Participants Who Completed Protocol P05691 (P05692)
A Multicenter, Double-Blind, Fixed-Dose, Long-Term Extension Trial of the Safety of Asenapine in Subjects Diagnosed With Bipolar 1 Disorder Who Completed Protocol P05691 (Formerly 041044) (Phase3B, Protocol P05692 [Formerly 041045])
Status: Enrolling
Updated:  4/22/2014
Clinical Research Facility
mi
from
Dallas, TX
Long-Term Safety Extension Trial of Asenapine in Bipolar 1 Disorder Participants Who Completed Protocol P05691 (P05692)
A Multicenter, Double-Blind, Fixed-Dose, Long-Term Extension Trial of the Safety of Asenapine in Subjects Diagnosed With Bipolar 1 Disorder Who Completed Protocol P05691 (Formerly 041044) (Phase3B, Protocol P05692 [Formerly 041045])
Status: Enrolling
Updated: 4/22/2014
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Long-Term Safety Extension Trial of Asenapine in Bipolar 1 Disorder Participants Who Completed Protocol P05691 (P05692)
A Multicenter, Double-Blind, Fixed-Dose, Long-Term Extension Trial of the Safety of Asenapine in Subjects Diagnosed With Bipolar 1 Disorder Who Completed Protocol P05691 (Formerly 041044) (Phase3B, Protocol P05692 [Formerly 041045])
Status: Enrolling
Updated:  4/22/2014
Clinical Research Facility
mi
from
Salt Lake City, UT
Long-Term Safety Extension Trial of Asenapine in Bipolar 1 Disorder Participants Who Completed Protocol P05691 (P05692)
A Multicenter, Double-Blind, Fixed-Dose, Long-Term Extension Trial of the Safety of Asenapine in Subjects Diagnosed With Bipolar 1 Disorder Who Completed Protocol P05691 (Formerly 041044) (Phase3B, Protocol P05692 [Formerly 041045])
Status: Enrolling
Updated: 4/22/2014
Clinical Research Facility
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
A 6 Week Randomized Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD (Adults With Attention Deficit/Hyperactivity )
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  4/27/2014
Sarkis Clinical Trials
mi
from
Gainesville, FL
A 6 Week Randomized Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD (Adults With Attention Deficit/Hyperactivity )
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 4/27/2014
Sarkis Clinical Trials
mi
from
Gainesville, FL
Click here to add this to my saved trials
A 6 Week Randomized Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD (Adults With Attention Deficit/Hyperactivity )
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  4/27/2014
Miami Research
mi
from
South Miami, FL
A 6 Week Randomized Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD (Adults With Attention Deficit/Hyperactivity )
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 4/27/2014
Miami Research
mi
from
South Miami, FL
Click here to add this to my saved trials
A 6 Week Randomized Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD (Adults With Attention Deficit/Hyperactivity )
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  4/27/2014
Capstone Clinical Research
mi
from
Libertyville, IL
A 6 Week Randomized Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD (Adults With Attention Deficit/Hyperactivity )
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 4/27/2014
Capstone Clinical Research
mi
from
Libertyville, IL
Click here to add this to my saved trials
A 6 Week Randomized Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD (Adults With Attention Deficit/Hyperactivity )
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  4/27/2014
Psychiatric Associates
mi
from
Overland Park, KA
A 6 Week Randomized Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD (Adults With Attention Deficit/Hyperactivity )
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 4/27/2014
Psychiatric Associates
mi
from
Overland Park, KA
Click here to add this to my saved trials
A 6 Week Randomized Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD (Adults With Attention Deficit/Hyperactivity )
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  4/27/2014
University Kentucky Psychiatry
mi
from
Lexington, KY
A 6 Week Randomized Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD (Adults With Attention Deficit/Hyperactivity )
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 4/27/2014
University Kentucky Psychiatry
mi
from
Lexington, KY
Click here to add this to my saved trials
A 6 Week Randomized Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD (Adults With Attention Deficit/Hyperactivity )
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  4/27/2014
Pediatric Psychopharmacology & Adult ADHD Program, Massachusetts General Hospital
mi
from
Boston, MA
A 6 Week Randomized Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD (Adults With Attention Deficit/Hyperactivity )
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 4/27/2014
Pediatric Psychopharmacology & Adult ADHD Program, Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
A 6 Week Randomized Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD (Adults With Attention Deficit/Hyperactivity )
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  4/27/2014
Rochester Center for Behavioral Medicine
mi
from
Rochester Hills, MI
A 6 Week Randomized Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD (Adults With Attention Deficit/Hyperactivity )
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 4/27/2014
Rochester Center for Behavioral Medicine
mi
from
Rochester Hills, MI
Click here to add this to my saved trials
A 6 Week Randomized Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD (Adults With Attention Deficit/Hyperactivity )
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  4/27/2014
Behavioral Medicine Center
mi
from
Troy, MI
A 6 Week Randomized Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD (Adults With Attention Deficit/Hyperactivity )
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 4/27/2014
Behavioral Medicine Center
mi
from
Troy, MI
Click here to add this to my saved trials
A 6 Week Randomized Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD (Adults With Attention Deficit/Hyperactivity )
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  4/27/2014
St Charles Psychiatric Associates
mi
from
St. Charles, MO
A 6 Week Randomized Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD (Adults With Attention Deficit/Hyperactivity )
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 4/27/2014
St Charles Psychiatric Associates
mi
from
St. Charles, MO
Click here to add this to my saved trials
A 6 Week Randomized Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD (Adults With Attention Deficit/Hyperactivity )
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  4/27/2014
Center for Psychiatry and Behavioral Medicine, Inc.
mi
from
Las Vegas, NV
A 6 Week Randomized Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD (Adults With Attention Deficit/Hyperactivity )
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 4/27/2014
Center for Psychiatry and Behavioral Medicine, Inc.
mi
from
Las Vegas, NV
Click here to add this to my saved trials
A 6 Week Randomized Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD (Adults With Attention Deficit/Hyperactivity )
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  4/27/2014
Bioscience Research, Llc
mi
from
Mount Kisco, NY
A 6 Week Randomized Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD (Adults With Attention Deficit/Hyperactivity )
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 4/27/2014
Bioscience Research, Llc
mi
from
Mount Kisco, NY
Click here to add this to my saved trials
A 6 Week Randomized Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD (Adults With Attention Deficit/Hyperactivity )
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  4/27/2014
Duke University
mi
from
Durham, NC
A 6 Week Randomized Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD (Adults With Attention Deficit/Hyperactivity )
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 4/27/2014
Duke University
mi
from
Durham, NC
Click here to add this to my saved trials
A 6 Week Randomized Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD (Adults With Attention Deficit/Hyperactivity )
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  4/27/2014
Richard H. Weisler, MD, PA
mi
from
Raleigh, NC
A 6 Week Randomized Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD (Adults With Attention Deficit/Hyperactivity )
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 4/27/2014
Richard H. Weisler, MD, PA
mi
from
Raleigh, NC
Click here to add this to my saved trials
A 6 Week Randomized Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD (Adults With Attention Deficit/Hyperactivity )
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  4/27/2014
Sequoia Behavioral Healthcare
mi
from
Media, PA
A 6 Week Randomized Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD (Adults With Attention Deficit/Hyperactivity )
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 4/27/2014
Sequoia Behavioral Healthcare
mi
from
Media, PA
Click here to add this to my saved trials
A 6 Week Randomized Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD (Adults With Attention Deficit/Hyperactivity )
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  4/27/2014
FutureResearch Trials
mi
from
Austin, TX
A 6 Week Randomized Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD (Adults With Attention Deficit/Hyperactivity )
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 4/27/2014
FutureResearch Trials
mi
from
Austin, TX
Click here to add this to my saved trials
A 6 Week Randomized Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD (Adults With Attention Deficit/Hyperactivity )
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  4/27/2014
FutureResearch Trials Dallas, LP
mi
from
Dallas, TX
A 6 Week Randomized Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD (Adults With Attention Deficit/Hyperactivity )
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 4/27/2014
FutureResearch Trials Dallas, LP
mi
from
Dallas, TX
Click here to add this to my saved trials
A 6 Week Randomized Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD (Adults With Attention Deficit/Hyperactivity )
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  4/27/2014
Bayou City Research, Ltd.
mi
from
Houston, TX
A 6 Week Randomized Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD (Adults With Attention Deficit/Hyperactivity )
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 4/27/2014
Bayou City Research, Ltd.
mi
from
Houston, TX
Click here to add this to my saved trials
A 6 Week Randomized Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD (Adults With Attention Deficit/Hyperactivity )
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  4/27/2014
NeuroScience, Inc. (NSI)
mi
from
Herndon, VA
A 6 Week Randomized Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD (Adults With Attention Deficit/Hyperactivity )
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 4/27/2014
NeuroScience, Inc. (NSI)
mi
from
Herndon, VA
Click here to add this to my saved trials
Mentalization-Based Therapy to Prevent Suicidal Behavior in Adolescents With Bipolar Disorder
Mentalization-Based Therapy to Prevent Suicidal Behavior in Adolescents With Bipolar Disorder
Status: Enrolling
Updated:  4/30/2014
University of California at Los Angeles
mi
from
Los Angeles, CA
Mentalization-Based Therapy to Prevent Suicidal Behavior in Adolescents With Bipolar Disorder
Mentalization-Based Therapy to Prevent Suicidal Behavior in Adolescents With Bipolar Disorder
Status: Enrolling
Updated: 4/30/2014
University of California at Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Remote Exercise for Learning Anger and Excitation Management
Remote Exercise for Learning Anger and Excitation Management (RELAX)
Status: Enrolling
Updated:  5/6/2014
VA Pacific Islands Healthcare System
mi
from
Honolulu, HI
Remote Exercise for Learning Anger and Excitation Management
Remote Exercise for Learning Anger and Excitation Management (RELAX)
Status: Enrolling
Updated: 5/6/2014
VA Pacific Islands Healthcare System
mi
from
Honolulu, HI
Click here to add this to my saved trials
Autism Intervention Research Network for Behavioral Health (AIR-B II): Deployment Into Elementary Schools
Autism Intervention Research Network for Behavioral Health (AIR-B II): Network Activity A: Conduct Research on Evidence-Based Practices.
Status: Enrolling
Updated:  5/7/2014
UCLA Semel Institute
mi
from
Los Angeles, CA
Autism Intervention Research Network for Behavioral Health (AIR-B II): Deployment Into Elementary Schools
Autism Intervention Research Network for Behavioral Health (AIR-B II): Network Activity A: Conduct Research on Evidence-Based Practices.
Status: Enrolling
Updated: 5/7/2014
UCLA Semel Institute
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Autism Intervention Research Network for Behavioral Health (AIR-B II): Deployment Into Elementary Schools
Autism Intervention Research Network for Behavioral Health (AIR-B II): Network Activity A: Conduct Research on Evidence-Based Practices.
Status: Enrolling
Updated:  5/7/2014
Univ of Rochester Medical Center
mi
from
Rochester, NY
Autism Intervention Research Network for Behavioral Health (AIR-B II): Deployment Into Elementary Schools
Autism Intervention Research Network for Behavioral Health (AIR-B II): Network Activity A: Conduct Research on Evidence-Based Practices.
Status: Enrolling
Updated: 5/7/2014
Univ of Rochester Medical Center
mi
from
Rochester, NY
Click here to add this to my saved trials
Autism Intervention Research Network for Behavioral Health (AIR-B II): Deployment Into Elementary Schools
Autism Intervention Research Network for Behavioral Health (AIR-B II): Network Activity A: Conduct Research on Evidence-Based Practices.
Status: Enrolling
Updated:  5/7/2014
UPENN Map Center for Mental Health Policy and Services Research
mi
from
Philadelphia, PA
Autism Intervention Research Network for Behavioral Health (AIR-B II): Deployment Into Elementary Schools
Autism Intervention Research Network for Behavioral Health (AIR-B II): Network Activity A: Conduct Research on Evidence-Based Practices.
Status: Enrolling
Updated: 5/7/2014
UPENN Map Center for Mental Health Policy and Services Research
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Adherence in Patients Admitted to a Psychiatric Unit for Acute Psychosis: an Analysis of Serum Levels of Antipsychotics.
Determination of Adherence in Patients Admitted to a Psychiatric Unit for Decompensated Psychosis: an Analysis of Serum Levels of Antipsychotics.
Status: Enrolling
Updated:  5/12/2014
The Zucker Hillside Hospital
mi
from
Glen Oaks, NY
Adherence in Patients Admitted to a Psychiatric Unit for Acute Psychosis: an Analysis of Serum Levels of Antipsychotics.
Determination of Adherence in Patients Admitted to a Psychiatric Unit for Decompensated Psychosis: an Analysis of Serum Levels of Antipsychotics.
Status: Enrolling
Updated: 5/12/2014
The Zucker Hillside Hospital
mi
from
Glen Oaks, NY
Click here to add this to my saved trials
Transcranial Magnetic Stimulation Treatment for Generalized Anxiety Disorder
Transcranial Magnetic Stimulation Treatment for Generalized Anxiety Disorder: Substudy #2
Status: Enrolling
Updated:  5/13/2014
The Hartford Hospital
mi
from
Hartford, CT
Transcranial Magnetic Stimulation Treatment for Generalized Anxiety Disorder
Transcranial Magnetic Stimulation Treatment for Generalized Anxiety Disorder: Substudy #2
Status: Enrolling
Updated: 5/13/2014
The Hartford Hospital
mi
from
Hartford, CT
Click here to add this to my saved trials
Memantine Treatment for Obsessive-compulsive Disorder and Generalized Anxiety Disorder
Differential Efficacy of Memantine for Obsessive-compulsive Disorder vs. Generalized Anxiety Disorder: an Open-label Trial
Status: Enrolling
Updated:  5/19/2014
UCLA
mi
from
Los Angeles, CA
Memantine Treatment for Obsessive-compulsive Disorder and Generalized Anxiety Disorder
Differential Efficacy of Memantine for Obsessive-compulsive Disorder vs. Generalized Anxiety Disorder: an Open-label Trial
Status: Enrolling
Updated: 5/19/2014
UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Relaxation Response Training for PTSD Prevention in US Military Personnel
Relaxation Response (RR) Training for PTSD Prevention in Soldiers a.k.a. "SPIRIT SMART" (Stemming PTSD, Increasing Resilience and Impeding Trauma in Service Members: Assessing Relaxation Response Training)
Status: Enrolling
Updated:  5/20/2014
William Beaumont Army Medical Center, Ft Bliss
mi
from
El Paso, TX
Relaxation Response Training for PTSD Prevention in US Military Personnel
Relaxation Response (RR) Training for PTSD Prevention in Soldiers a.k.a. "SPIRIT SMART" (Stemming PTSD, Increasing Resilience and Impeding Trauma in Service Members: Assessing Relaxation Response Training)
Status: Enrolling
Updated: 5/20/2014
William Beaumont Army Medical Center, Ft Bliss
mi
from
El Paso, TX
Click here to add this to my saved trials
Mindfulness-Based Relapse Prevention for Alcohol Use Disorders in Remission
Mindfulness-Based Relapse Prevention and Stress Reactivity in Alcohol Dependent Individuals: A Pilot Study
Status: Enrolling
Updated:  5/23/2014
University of Virginia School of Medicine
mi
from
Charlottesville, VA
Mindfulness-Based Relapse Prevention for Alcohol Use Disorders in Remission
Mindfulness-Based Relapse Prevention and Stress Reactivity in Alcohol Dependent Individuals: A Pilot Study
Status: Enrolling
Updated: 5/23/2014
University of Virginia School of Medicine
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Intranasal Oxytocin for the Treatment of Autism Spectrum Disorders
Intranasal Oxytocin for the Treatment of Autism Spectrum Disorders
Status: Enrolling
Updated:  5/27/2014
Montefiore Medical Center, Albert Einstein College of Medicine
mi
from
Bronx, NY
Intranasal Oxytocin for the Treatment of Autism Spectrum Disorders
Intranasal Oxytocin for the Treatment of Autism Spectrum Disorders
Status: Enrolling
Updated: 5/27/2014
Montefiore Medical Center, Albert Einstein College of Medicine
mi
from
Bronx, NY
Click here to add this to my saved trials
Eye Injections of Bevacizumab to See if Medication Helps to Lower Risk of Scar Tissue Development in the Retina and Repeated Retinal Detachment.
A Prospective Pilot Study Evaluating the Effect of Intravitreal Injection of Bevacizumab on Recurrent Retinal Detachment Due to Proliferative Vitreoretinopathy
Status: Enrolling
Updated:  5/27/2014
Mid Atlantic Retina- Wills Eye Institute
mi
from
Philadelphia, PA
Eye Injections of Bevacizumab to See if Medication Helps to Lower Risk of Scar Tissue Development in the Retina and Repeated Retinal Detachment.
A Prospective Pilot Study Evaluating the Effect of Intravitreal Injection of Bevacizumab on Recurrent Retinal Detachment Due to Proliferative Vitreoretinopathy
Status: Enrolling
Updated: 5/27/2014
Mid Atlantic Retina- Wills Eye Institute
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Sensorimotor Affect Relationship-based Therapy (SMART) for Children With Autism Spectrum Disorders Ages 2-12
Sensorimotor Affect Relationship-based Therapy (SMART) for Children With Autism Spectrum Disorders Ages 2-12
Status: Enrolling
Updated:  5/30/2014
Nationwide Children's Hospital Hilliard Close to Home
mi
from
Hilliard, OH
Sensorimotor Affect Relationship-based Therapy (SMART) for Children With Autism Spectrum Disorders Ages 2-12
Sensorimotor Affect Relationship-based Therapy (SMART) for Children With Autism Spectrum Disorders Ages 2-12
Status: Enrolling
Updated: 5/30/2014
Nationwide Children's Hospital Hilliard Close to Home
mi
from
Hilliard, OH
Click here to add this to my saved trials
New Treatment for Alcohol and Nicotine Dependence
High and Low Dose Topiramate for the Treatment of Alcohol-Dependent Smokers
Status: Enrolling
Updated:  6/3/2014
The University of California, San Diego
mi
from
La Jolla, CA
New Treatment for Alcohol and Nicotine Dependence
High and Low Dose Topiramate for the Treatment of Alcohol-Dependent Smokers
Status: Enrolling
Updated: 6/3/2014
The University of California, San Diego
mi
from
La Jolla, CA
Click here to add this to my saved trials
New Treatment for Alcohol and Nicotine Dependence
High and Low Dose Topiramate for the Treatment of Alcohol-Dependent Smokers
Status: Enrolling
Updated:  6/3/2014
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
New Treatment for Alcohol and Nicotine Dependence
High and Low Dose Topiramate for the Treatment of Alcohol-Dependent Smokers
Status: Enrolling
Updated: 6/3/2014
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials